OX40/TNFRSF4 Antibody (977974) [Alexa Fluor™ Plus 594]

• Clone: 977974
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 594

OX40/TNFRSF4 Antibody (977974) [Alexa Fluor™ Plus 594] Summary

• Specificity: Detects human OX40/TNFRSF4 in direct ELISAs
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OX40/TNFRSF4 Antibody (977974) [Alexa Fluor™ Plus 594]

• ACT-135
• ACT35 antigen
• ACT35ATC35 antigen
• CD134 antigen
• CD134
• Ly-70
• OX40 cell surface antigen
• OX40 homologue
• OX40
• OX40L receptor
• OX40lymphoid activation antigene ACT35
• TAX transcriptionally-activated glycoprotein 1 receptor
• tax-transcriptionally activated glycoprotein 1 receptor
• TNFRSF4
• tumor necrosis factor receptor superfamily member 4
• tumor necrosis factor receptor superfamily, member 4
• Txgp1
• TXGP1L
• TXGP1LOX40 antigen

Background

OX40 (CD134; TNFRSF4) is a T cell co‑stimulatory molecule of the TNF receptor superfamily that coordinates with other membrane-bound co‑stimulators such as CD28, CD40, CD30, CD27 and 4-1BB (1‑3). OX40 is expressed on naïve CD4⁺ T cells only after engagement of the TCR by antigen presenting cells (APC; dendritic and B cells), and co‑stimulation by CD40/CD40 ligand and CD28/B7. It is maximal at 2‑5 days post activation, or 4 hours post reactivation of memory T cells (3‑6). Human OX40 is a 48 kDa type I transmembrane glycoprotein with a 28 amino acid (aa) signal sequence, a 185 aa extracellular domain (ECD) that has four TNFR-Cys repeats and an O-glycosylated hinge region, a 20 aa transmembrane segment, and a 41 aa cytoplasmic domain (3). The ECD of human OX40 shows 71%, 68%, 67%, 64% and 64% aa identity with feline, canine, rabbit, mouse and rat OX40 ECD, respectively. Engagement of OX40 on activated CD4⁺ T cells by OX40 ligand on activated dendritic cells promotes T cell survival and proliferation, prolongs the immune response, and enhances the number of cells making the transition from effector to memory T cells (1‑6). OX40 signal transduction includes binding TNF receptor-associated factors (TRAFs), and activating NF kappa B and PI3 kinase to enhance expression of cytokines, antiapoptotic Bcl-2 family members, survivin and the chemokine receptor CXCR5 (5‑8). CXCR5 promotes T cell migration to germinal centers to deliver B cell help (5). Studies using knockout or transgenic mice, and agonistic or blocking antibodies, show that OX40/OX40L interaction is critical for establishing or reactivating memory T cells and breaking immune tolerance (9). Blockade of OX40 engagement is efficacious in animal models of allergic airway inflammation, graft-versus-host disease and autoimmune disease (10‑14).

 

1. Salek-Ardakani, S. and M. Croft (2006) Vaccine 24:872.
2. Hori, T. (2006) Int. J. Hematol. 83:17.
3. Latza, U. et al. (1994) Eur. J. Immunol. 24:677.
4. Murata, K. et al. (2000) J. Exp. Med. 191:365.
5. Fillatreau, S and D. Gray (2003) J. Exp. Med. 197:195.
6. Gramaglia, I. et al. (1998) J. Immunol. 161:6510.
7. Rogers, P.R. et al. (2001) Immunity 15:445.
8. Song, J. et al. (2005) Immunity 22:621.
9. Bansal-Pakala, P. et al. (2001) Nat. Med. 7:907.
10. Salek-Ardakani, S. et al. (2003) J. Exp. Med. 198:315.
11. Jember, A. G. et al. (2001) J. Exp. Med. 193:387.
12. Demirci, G. et al. (2004) J. Immunol. 172:1691.
13. Blazar, B.R. et al. (2003) Blood 101:3741.
14. Higgins, L.M. et al. (1999) J. Immunol. 162:486.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.